Transcode Therapeutics (RNAZ) Accumulated Depreciation (2021 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Accumulated Depreciation came in at $411196.0 in Q1 2026, up 26.81% YoY from $324256.0 in Q1 2025, and up 6.18% on a QoQ basis from $387260.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Accumulated Depreciation (2021 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Accumulated Depreciation data on file, last reported at $411196.0 in Q1 2026.
- Quarterly Accumulated Depreciation rose 26.81% year-over-year to $411196.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $411196.0 (up 26.81% YoY) and the FY2025 annual result came in at $387260.0, up 24.6% from the prior year.
- Accumulated Depreciation advanced to $411196.0 in Q1 2026, from $387260.0 in the prior quarter.
- In the past five years, Accumulated Depreciation ranged from a high of $411196.0 in Q1 2026 to a low of $62855.0 in Q1 2022.
- A 5-year average of $255563.7 and a median of $295507.0 in 2024 frame the typical range for Accumulated Depreciation.
- Annual changes were most pronounced in 2022 — Accumulated Depreciation jumped 239.02% — and 2025, when it fell 0.41%.
- Tracing RNAZ's Accumulated Depreciation over 5 years: stood at $139860.0 in 2022, then jumped by 88.29% to $263343.0 in 2023, then increased by 18.03% to $310813.0 in 2024, then increased by 24.6% to $387260.0 in 2025, then advanced by 6.18% to $411196.0 in 2026.
- The last three Accumulated Depreciation figures came in at $411196.0 (Q1 2026), $387260.0 (Q4 2025), and $342479.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 411,196.00 |
| Dec 31, 2025 | 387,260.00 |
| Sep 30, 2025 | 342,479.00 |
| Jun 30, 2025 | 337,698.00 |
| Mar 31, 2025 | 324,256.00 |
| Dec 31, 2024 | 310,813.00 |
| Sep 30, 2024 | 343,891.00 |
| Jun 30, 2024 | 327,860.00 |
| Mar 31, 2024 | 295,507.00 |
| Dec 31, 2023 | 263,343.00 |
| Sep 30, 2023 | 231,688.00 |
| Jun 30, 2023 | 200,469.00 |
| Mar 31, 2023 | 169,500.00 |
| Dec 31, 2022 | 139,860.00 |
| Sep 30, 2022 | 110,355.00 |
| Jun 30, 2022 | 85,553.00 |
| Mar 31, 2022 | 62,855.00 |
| Dec 31, 2021 | 41,254.00 |